Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBIT Margin (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed EBIT Margin for 5 consecutive years, with 9.78% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin rose 2553.0% year-over-year to 9.78%, compared with a TTM value of 11.4% through Dec 2025, up 2217.0%, and an annual FY2025 reading of 11.4%, up 2217.0% over the prior year.
  • EBIT Margin was 9.78% for Q4 2025 at Kiniksa Pharmaceuticals International, down from 13.28% in the prior quarter.
  • Across five years, EBIT Margin topped out at 46.82% in Q3 2022 and bottomed at 253.55% in Q3 2021.
  • Average EBIT Margin over 5 years is 32.85%, with a median of 6.51% recorded in 2023.
  • The sharpest move saw EBIT Margin skyrocketed 30037bps in 2022, then crashed -6312bps in 2023.
  • Year by year, EBIT Margin stood at 192.75% in 2021, then skyrocketed by 98bps to 4.08% in 2022, then skyrocketed by 102bps to 0.1% in 2023, then crashed by -16315bps to 15.75% in 2024, then soared by 162bps to 9.78% in 2025.
  • Business Quant data shows EBIT Margin for KNSA at 9.78% in Q4 2025, 13.28% in Q3 2025, and 12.86% in Q2 2025.